Alvotech (NAS:ALVO)
$ 12.13 -0.05 (-0.41%) Market Cap: 3.67 Bil Enterprise Value: 4.87 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 9/100

Alvotech SA at Morgan Stanley Sustainable Finance Summit Transcript

May 22, 2023 / 02:15PM GMT
Release Date Price: $8.51 (+2.16%)
Thibault Boutherin
Morgan Stanley, Research Division - Equity Analyst

Good morning and good afternoon, everyone. My name is Thibault Boutherin. I'm part of the European pharma team, and I am joined on this call by my colleague, Mike Canfield, Head of EMEA Sustainability Research at Morgan Stanley. Please note that this webcast is for Morgan Stanley's clients and appropriate Morgan Stanley's employees only. This webcast is not for members of the press. If you are a member of the press, please disconnect and reach out separately. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures.

We are pleased to have with us Ming Li, Chief Strategy Officer at Alvotech for this session on affordable biologics. Ming, thank you for joining us.

Questions & Answers

Thibault Boutherin
Morgan Stanley, Research Division - Equity Analyst

And before we get into the details of Alvotech's ESG strategy

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot